echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > "Drug Curry Jun" a hundred flowers in full bloom! Fosun, Hengrui, Qilu and other class 1 new drug outbreak; IL-5, IL-6, ADC and other popular target drug piles to accept ...

    "Drug Curry Jun" a hundred flowers in full bloom! Fosun, Hengrui, Qilu and other class 1 new drug outbreak; IL-5, IL-6, ADC and other popular target drug piles to accept ...

    • Last Update: 2020-07-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Read: The Latest! Drug Approvals !----- This Week's Watch: International Drug DynamicsCoren "Ute alcohol injection" the first domestic imitation of the listingthe second domestic HIV drug " Azftin tablets" to apply for productionthe world's first FDA-approved oral TPO-RA drug for CLD-related platelet reduction is available in China! The current issue (July 3-10) international and domestic drug approvals are acceleratinginternationally, Qwo (Dissolved Tissue Clostridium DPharade) for the treatment of orange peel tissue was approved by the FDA;in China, six drugs were approved in the current period, one of which was withdrawn by an enterprisefocus on accepted drugs, of which 6 new drugs were accepted, 17 kinds of imported drugs, 55 generic drugs, the specific dynamics are as follows: domestic review and approval, new acceptance this week CDE new report of the production acceptance number 113, a total of 78 varietiesof which six new domestic drugs were accepted: including Hengrui's Haiqupopa ethanolamine tablets, real-life Azfdin tablets, and North China Pharmaceutical's recombinant human-derived anti-rabies virus sing-injectionreceived 17 imported drugs, received 55 generic drugs, more dynamic smaller as follows: First, three heavy domestic drugs 1haiquupa ethanolamine tablets, is an oral absorption of Aucryao-non-peptide platelet receptor (TPO-R) agonists, mainly used for the treatment of glucosteroid corticosteroids, immunoglobulin or spleen removal effect is not good chronic primary immunosyputic plateletreduction treatment, Shanghai Fosun Pharma recently announced that its first small-molecule innovative drug Sukexin (Malay acid Avalupapa tablet tablet) has been officially approved for use in China for the treatment of adult patients with chronic liver disease (CLD)-related platelet reduction associated with diagnostic operation or surgeryAvalquopa is the world's first FDA-approved oral platelet receptor agonis (TPO-RA) for CLD-related platelet reductionAccording to foerpharma's press release, Avalquo Popa has become the only platelet drug in China to be recommended by guidelines on liver diseasesimilar productsare: AiQu Popa, Reed Popa, Romistin and platelet sefactory, however, the sea-cupa is more efficient and less toxic than AiqupopaFosun AvalQupo Popa than Hengrui Haiqu Popa earlier layout, Hengrui, Fosun is bound to be the domestic platelet reduction market heavyweight opponents2Azftin tablets, are the innovative anti-HIV dual-target drugs developed by real-world organisms, the world's first HIV reverse transcriptase and auxiliary protein Vif dual-target inhibitor drugs, the first anti-HIV oral drug with independent intellectual property rights in Chinathe new drug has now been registered with seven clinical trials for the treatment of AIDS3Recombined human-derived anti-rabies virus singic injection, is a new class of new drugs independently developed by North China Pharmaceuticals, at present, the domestic passive immunoformulationist agents that can be used for rabies virus exposure prevention for anti-rabies serum and rabies patient immunoglobulin, there is no recombinant anti-rabies virus monoantitherapy drug listed for sale, North China Pharmaceutical selling the first domestic declarationtwo, four imported heavy-duty drugs, the giant pooled tocilizumab, is roche original research of a recombinant humanized anti-IL-6 monotogens, currently approved in China for the treatment of rheumatoid arthritis (RA) and systemic juvenile acute ejaphd arthritis (sJIA), this is the third domestic application for new adaptationMepolizumab, a targeted IL-5 humanized monoclonal antibody developed by GlaxoSmithKline, is the first declared IL-5 monotophono in China, and based on an experiment registered on chinadrugtrials, the indicationis is asthma, is a new antifungal drug developed by Basilea Pharmaceutica, which has exclusive rights to develop and sell in china and several countries in the Asia-Pacific regionhas been approved in more than 40 countries and regions around the world, this time submitted in China two specifications: sulfuric acid Aisaconazole capsules and injection of aisaconazole, Takeda's new ADC drug injection with CD30 has also filed a second listing application in Chinathree, two generic drugs, the first imitation? First review? Collum wants to take the lead and enter the 15.2 billion yuan domestic shadow market: data show that in 2019 domestic photocreator sales of about 15.2 billion yuan, of which magnetic resonance contrast agent accounted for 12.9%at present, there are 8 kinds of approved anti-venom contrast agents, including the diamine injection, anti-sterol injection, antimony injection has not yet been approved generic drugs, Collum Pharmaceuticals as the first drug-listed generics for the tantalum injection, is expected to obtain the first domestic imitation of the variety, in addition to columin, there is iodine paol injection, sodium diazepam injection has been reportedfirst review? The application for listing of Theron Antibacterial Drug was accepted: the Klinmycin phosphate injection was developed by The company, Famasapjanthe original research products have not yet been listed in China, in 2019 China's public medical institutions terminal klinmycin injection sales reached 2.302 billion yuanLuoxin this time to copy 3 categories of listing applications, approved can be directly listed for sale, as if through the consistency evaluation currently has a total of 74 enterprises with this variety of production approvals, but there are no enterprises through consistency evaluation data source: drug-intelligence consistency evaluation progress database domestic review and approval, new dynamicthis this week CDE has 18 acceptance numbers (15 varieties) reported production status updates, of which, 10 status updates "in approval", the specific dynamics are as follows: glutacryd di acid capsules (nine phase 1) 450mg specification approval has been issued, NMPA did not approve, on July 8 Green Valley Pharmaceuticals said that the nine new specifications were not approved, not not approved, but on April 2 to NMPA to withdraw the 450mg specification of ganlutna capsule listing application said it had resubmitted its application because the 450mg specification needed to be updated data source: drug intelligence data, enterprise announcements and other network public data sources: drug intelligence network, enterprise announcements and other network public information.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.